

BRITISH SOCIETY OF TOXICOLOGICAL PATHOLOGY

CONTINUING EDUCATION SYMPOSIUM 1:
TOXICOLOGY and PATHOLOGY

Cambridge

Tuesday 26th – Thursday 28th March 2019



Approximately 17.25 hours of educational activity will be recorded on Attendance Certificates

Approved by the Royal Society of Biology for the purposes of CPD, this event may be counted as 51 credits

PROVISIONAL PROGRAMME as at 6th February 2019

Tuesday 26th March 2019	
08.45 - 09.15	Registration
09.15 - 09.30	Introduction by the Scientific Organiser <i>Ian Taylor, Envigo, UK</i>
09.30 - 10.15	Descriptive pathology skills & data recording in toxicological & experimental pathology <i>Cheryl Scudamore, Envigo, UK</i>
10.15 - 10.45	Break
10.45 - 12.00	Immunological techniques in toxicological pathology <i>Stewart Jones, AstraZeneca, UK</i>
12.00 - 13.00	<i>In situ</i> techniques using nucleic acids <i>Kevin Randall, Medicines Discovery Catapult, UK</i>
13.00 - 14.00	Lunch
14.00 - 14.45	Approaches to the analysis & interpretation of toxicology clinical pathology data <i>Peter Cotton, AstraZeneca, UK</i>
14.45 - 15.15	Break
15.15 - 16.45	Workshop/Case Studies: Haematology & clinical chemistry <i>Peter Cotton, AstraZeneca/Ian Roman, GlaxoSmithKline, UK</i>

Wednesday 27th March 2019	
08.45 - 09.30	Safety pharmacology in drug discovery & development/case studies <i>Speaker - tbc</i>
09.30 - 10.30	<i>In vivo</i> imaging - overview/case histories <i>Juliana Maynard, Medicines Discovery Catapult, UK</i>
10.30 - 11.00	Break
11.00 - 12.00	Non-animal approaches to safety assessment <i>Carl Westmoreland, Unilever, UK</i>
12.00 - 13.00	Lunch
13.00 - 14.00	Pharmacogenetics & drug toxicity <i>Ann Daly, Institute of Cellular Medicine, Newcastle University, UK</i>
14.00 - 15.00	Animal models in drug development & discovery <i>Peter Clements, GlaxoSmithKline, UK</i>
15.00 - 15.30	Break
15.30 - 16.15	Animal models in drug development & discovery – case presentations <i>Peter Clements, GlaxoSmithKline, UK</i>
16.15 - 17.15	Use of nonclinical data for risk assessment & risk management in the clinic: Dose selection, dose escalation & monitoring <i>Jim Bush, Covance Clinical Research Unit, UK</i>

You are advised that the programme timings, lecture title and speakers may be subject to change without notice

Registered Charity No: 1043793

BRITISH SOCIETY OF TOXICOLOGICAL PATHOLOGY

CONTINUING EDUCATION SYMPOSIUM 1:

TOXICOLOGY and PATHOLOGY

Cambridge

Tuesday 26th – Thursday 28th March 2019



Approximately 17.25 hours of educational activity will be recorded on Attendance Certificates

Approved by the Royal Society of Biology for the purposes of CPD, this event may be counted as 51 credits

PROVISIONAL PROGRAMME as at 6th February 2019

Thursday 28th March 2019	
08.45 - 09.45	Reproductive toxicology <i>Louise Youngs, Syngenta, UK</i>
09.45 - 10.45	Is it adverse? Introduction, case histories & interactive discussion – Part I <i>Jan Klapwijk, GlaxoSmithKline, UK</i>
10.45 - 11.15	Break
11.15 - 12.15	Nonclinical Safety Assessment of Biologics <i>Lolke de Haan, Medimmune, UK</i>
12.15 - 13.15	Lunch
13.15 - 14.00	Non-pharma – adversity – case histories <i>John Foster, Consultant Pathologist, UK</i>
14.00 - 15.00	A regulatory perspective on pathology data <i>David Jones, MHRA, UK</i>
15.00 - 15.30	Break
15.30 - 16.45	Is it adverse? Case histories & interactive discussion – Part II <i>Jan Klapwijk, GlaxoSmithKline, UK</i>
16.45 - 17.00	Closing remarks by the Scientific Organiser

You are advised that the programme timings, lecture title and speakers may be subject to change without notice

Registered Charity No: 1043793